These data indicate the ability of these DRD3 antagonists to be effective anti-GBM treatments: while the BBB is often compromised at the tumor site, drugs that penetrate into the non-tumor brain have a better potential to target GBM cells that have already escaped from the main tumor mass. The gene discussed is DRD3; the disease is glioblastoma.